Basilea Pharmaceutica (XSWX:BSLN) FFO


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
62 GF Score
Price CHF51.90
GF Value CHF57.38
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica FFO?

FFO (Funds from operations) only applies to REITs.

XSWX:BSLN
62GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF51.90 is trading 9.6% below its estimated GF Value™ of CHF57.38. GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.

Key valuation signals for XSWX:BSLN:

  • FFO:
  • GF Value™: CHF57.38 vs. price of CHF51.90 (9.6% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score

Get the complete analysis for XSWX:BSLN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF51.90
Price
CHF57.38
GF Value